Back

Red yeast rice-derived MKA ameliorates cardiac hypertrophy in hypertensive rats by inhibiting ERK1/2/c-Fos pathway

Tan, R.; Yang, D.; Liu, K.; LIU, J.; Li, N.; Sun, M.; Tan, X.; Hu, Q.; Zhang, C.

2026-03-13 pharmacology and toxicology
10.64898/2026.03.10.710945 bioRxiv
Show abstract

BackgroundCardiac hypertrophy is a key pathological process in hypertensive heart failure, yet current antihypertensive therapies do not directly target it. Red yeast rice (RYR), rich in monacolin K {beta}-hydroxy acid (MKA), is known for lipid-lowering effects, but its potential to ameliorate cardiac hypertrophy is unreported. PurposeTo investigate the effects of RYR-derived MKA on cardiac hypertrophy in spontaneously hypertensive rats (SHR) and elucidate its molecular mechanisms. MethodsSpontaneously hypertensive rats (SHR) were treated with 0.6% red yeast rice for 8 weeks to assess its effects on blood pressure, cardiac function (echocardiography), cardiac hypertrophy and fibrosis (histopathology), and multi-organ toxicity (histopathology). A multigenerational study was conducted to evaluate protective effects in offspring. Network pharmacology and transcriptomic analysis were integrated to predict molecular targets, which were subsequently validated by molecular docking and experiments. ResultsEight-week RYR treatment significantly reduced blood pressure, inhibited cardiac hypertrophy and fibrosis, and improved cardiac function without gender differences. No pulmonary, hepatic, or renal toxicity was observed. Offspring from treated parents exhibited further reduced hypertrophy upon continued treatment. Mechanistically, MKA bound ERK1/2 with high affinity, inhibiting its phosphorylation and downstream c-Fos expression, thereby downregulating hypertrophy markers. ConclusionRed yeast rice improves hypertensive cardiac hypertrophy via MKA-mediated inhibition of the ERK1/2/c-Fos pathway. Its multi-organ safety and transgenerational effects offer a novel dual-therapy strategy for hypertension and cardiac hypertrophy. Graphic abstract O_FIG O_LINKSMALLFIG WIDTH=139 HEIGHT=200 SRC="FIGDIR/small/710945v1_ufig1.gif" ALT="Figure 1"> View larger version (57K): org.highwire.dtl.DTLVardef@cbb85org.highwire.dtl.DTLVardef@1eb399dorg.highwire.dtl.DTLVardef@13746dorg.highwire.dtl.DTLVardef@140c512_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 8%
19.3%
2
Frontiers in Pharmacology
100 papers in training set
Top 0.1%
19.3%
3
Journal of Translational Medicine
46 papers in training set
Top 0.1%
3.8%
4
Scientific Reports
3102 papers in training set
Top 33%
3.7%
5
BioMed Research International
25 papers in training set
Top 1%
2.4%
6
BMC Cardiovascular Disorders
14 papers in training set
Top 0.7%
2.2%
50% of probability mass above
7
Frontiers in Cardiovascular Medicine
49 papers in training set
Top 1%
2.0%
8
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.1%
1.9%
9
Journal of the American Heart Association
119 papers in training set
Top 3%
1.9%
10
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 1%
1.8%
11
American Journal of Physiology-Heart and Circulatory Physiology
32 papers in training set
Top 0.6%
1.8%
12
F1000Research
79 papers in training set
Top 2%
1.7%
13
ACS Omega
90 papers in training set
Top 2%
1.4%
14
BMJ Open Diabetes Research & Care
15 papers in training set
Top 0.7%
1.3%
15
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.6%
1.1%
16
British Journal of Pharmacology
34 papers in training set
Top 0.3%
1.0%
17
Open Heart
19 papers in training set
Top 0.9%
1.0%
18
Frontiers in Endocrinology
53 papers in training set
Top 2%
1.0%
19
Hypertension
32 papers in training set
Top 0.6%
1.0%
20
eLife
5422 papers in training set
Top 51%
1.0%
21
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.6%
1.0%
22
Alzheimer's Research & Therapy
52 papers in training set
Top 1%
0.9%
23
Cell Discovery
54 papers in training set
Top 4%
0.9%
24
BMC Infectious Diseases
118 papers in training set
Top 4%
0.9%
25
Toxicological Sciences
38 papers in training set
Top 0.5%
0.8%
26
Biomedicines
66 papers in training set
Top 2%
0.8%
27
Gene
41 papers in training set
Top 2%
0.8%
28
Clinical and Translational Science
21 papers in training set
Top 0.9%
0.8%
29
Clinical Pharmacology & Therapeutics
25 papers in training set
Top 0.6%
0.8%
30
Frontiers in Genetics
197 papers in training set
Top 8%
0.8%